Navigation Links
Syndax Announces Start of NCI Sponsored Phase 2 Study of Entinostat in Combination in Triple Negative Breast Cancer
Date:3/1/2011

WALTHAM, Mass., March 1, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, announced the National Cancer Institute (NCI) will sponsor a multi-center phase 2 study of Syndax's lead product entinostat, a novel inhibitor of histone deacetylases (HDAC), and anastrozole, an aromatase inhibitor, in postmenopausal women with operable triple negative breast cancer to evaluate biomarkers and surrogates for response. The trial, to be conducted under a Cooperative Research and Development Agreement (CRADA) executed between the NCI and Syndax, will investigate whether patient tumors can be reprogrammed to express estrogen receptor and render them to be sensitive to hormonal agents. This trial is based on animal data being published in the March 1, 2011, issue of Cancer Research.

Laboratory studies by Dr. Angela Brodie, professor of pharmacology and experimental therapeutics, and Gauri J. Sabnis, Ph.D., assistant professor of pharmacology and experimental therapeutics at the University of Maryland School of Medicine, in collaboration with Saraswati Sukumar, M.S., Ph.D., professor of oncology and pathology at the Johns Hopkins University School of Medicine, provided the basis for the phase 2 clinical trial. Their work demonstrates that entinostat induces hormone sensitivity in an animal model of triple negative breast cancer and that the combination with aromatase inhibitors prevents tumor growth as well as tumor metastasis.

"In the pre-clinical study that is being published in Cancer Research we demonstrated that entinostat can induce re-expression of estrogen receptor and aromatase in triple negative breast cancer cell lines and render them sensitive to an aromatase inhibitor," said Saranya Chumsri, M.D., assistant professor of medicine at the University of Maryland School of Medicine and a medical oncologist at the University of Maryland Marlene and Stewart Greenebaum Cancer Center, principal investigator
'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Syndax Announces Publication of Entinostat NSCLC Data in Cancer Research
2. Syndax Pharmaceuticals to Present at Biotech Showcase 2011
3. Syndax Pharmaceuticals Entinostat in Combination Shows Activity in Breast Cancer
4. Syndax Pharmaceuticals Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients
5. Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat
6. Syndax Pharmaceuticals to Present at Sachs Biotech in Europe Investor Forum
7. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
8. K-V Pharmaceutical Company Announces $200 Million Private Debt Offering
9. Dehaier Medical Announces March Investor Presentations
10. Rigel Announces Fourth Quarter and Year End 2010 Financial Results
11. Jazz Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Results Conference Call on March 7
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  Decision Resources Group ... the United States , 54 percent ... BRAF inhibitor Tafinlar for BRAF -mutation-positive unresectable ... have prescribed GlaxoSmithKline,s MEK inhibitor Mekinist. Among current ... (42 percent and 43 percent, respectively) expects to ...
(Date:9/18/2014)... , Sept. 18, 2014  ADM Tronics ... DeNovi , Ph.D. to its corporate Advisory Board ... an instructor at the Harvard Medical School and ... Rome.  He received his Masters degree in Electronics ... Systems from the University of Bologna. After spending a ...
(Date:9/18/2014)... , Sept. 18, 2014  A $3 million grant ... the University of Michigan to establish a national center ... Glenn Center for Aging Research at U-M will focus ... can slow the effects of aging and postpone diseases ... aging that can help develop medications that may help ...
Breaking Medicine Technology:At One Year Post-Launch, Approximately One Half of Surveyed U.S. Medical Oncologists Have Prescribed Single-Agent Tafinlar and Mekinist to Their Malignant Melanoma Patients 2ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 2ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 3$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 3
(Date:9/18/2014)... 2014 (HealthDay News) -- Daily supplements of selenium or ... development of age-related cataracts among men, a new study ... or both could help prevent cataracts. To investigate this ... Harvard Medical School in Boston, and his colleagues examined ... vitamin E. The trial was initially designed to study ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 TayganPoint ... announced today that President and co-founder John Cassimatis ... Innovation Award Winners for 2014, recognizing the region’s ... as an emerging executive of the year. , ... and life sciences that continue to shape the ...
(Date:9/18/2014)... 2014 Stealth Health Revolution co-founders, ... and Frank Davis, founder of Food for Health ... pleased to announce the new recipe book, "The ... nutrition-packed meals using Activz whole-food powders." The ... in the Stealth Health Revolution mission ...
(Date:9/18/2014)... can expect to pay higher employee contributions for their ... resource officers about the impact of the Patient Protection ... Obamacare) conducted by the Darla Moore School of Business ... , Patrick Wright, a professor in strategic human resource ... HR Officers. The survey is distributed to more than ...
(Date:9/18/2014)... to develop tools that would allow them to clearly ... a neuron fires to the resulting behavior in a ... working to develop a range of new tools to ... such tool that provides a new way of mapping ... collaboration between Viviana Gradinaru (BS ,05), assistant professor of ...
Breaking Medicine News(10 mins):Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 3Health News:Survey: Fortune 500 employees can expect to pay more for health insurance 2Health News:Survey: Fortune 500 employees can expect to pay more for health insurance 3Health News:Sensing neuronal activity with light 2Health News:Sensing neuronal activity with light 3Health News:Sensing neuronal activity with light 4Health News:Sensing neuronal activity with light 5
... much about it. FlameEz.com is launched to provide the latest information ... of the most feared illnesses in middle and old age. ... ... Millions of Americans are affected by chronic inflammation without knowing much ...
... a ,must book-mark site,BETHESDA, Md., Jan. 14 The ... Foundation,s Web site -- www.cff.org -- the ... its "Best of the Web" review of 2008, the ... about cystic fibrosis. , , "This ...
... in French Hospital Market with More Than 130 ... ("Global Med" or the "Company") (OTC Bulletin Board: ... today announced that its subsidiary, Inlog, has licensed ... Serveur" in France) to nineteen additional hospitals during ...
... to Treat Diseases (HTDS) www.htdsmedical.com management ... agreement with Shenzhen Mellow Hope Pharm Industrial Co., ... biggest exporter of Biological Vaccines in China, and ... influenza, tetanus, diphtheria and other diseases; Blood based ...
... Quality Program ReviewsSEATTLE, Jan. 14 MetaStar, ... clinical guidelines and software from Milliman Care ... non-physician medical care reviews throughout the state. ... Milliman Care Guidelines (R) suite, MetaStar now ...
... insulin and oral human growth hormone formulations provide ... ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ... Cobalamin(TM) oral drug delivery product development programs. The ... B12 oral uptake mechanism to facilitate oral absorption ...
Cached Medicine News:Health News:Control of Inflammation May Benefit Many of the Most Feared Illnesses in Middle and Old Age 2Health News:Control of Inflammation May Benefit Many of the Most Feared Illnesses in Middle and Old Age 3Health News:Cystic Fibrosis Foundation Web Site Rated 'Best of the Web' 2Health News:Global Med Technologies(R)' Inlog Subsidiary Licensed EdgeTrack to 62 French Hospitals in 2008, Including 19 Hospitals in Q4 2008 2Health News:Global Med Technologies(R)' Inlog Subsidiary Licensed EdgeTrack to 62 French Hospitals in 2008, Including 19 Hospitals in Q4 2008 3Health News:Hard To Treat Diseases (HTDS) in Merger Talks with Mellow Hope, China 2Health News:Milliman Care Guidelines(R) Replaces Multiple Guideline Sets for Wisconsin QIO 2Health News:Milliman Care Guidelines(R) Replaces Multiple Guideline Sets for Wisconsin QIO 3Health News:Access Pharmaceuticals Provides an Update on Advances In Its Cobalamin(TM) Oral Drug Delivery Product Development 2Health News:Access Pharmaceuticals Provides an Update on Advances In Its Cobalamin(TM) Oral Drug Delivery Product Development 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: